Patents by Inventor Jean-Claude Tardif

Jean-Claude Tardif has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030181520
    Abstract: The present invention is a method to increase the lumen diameter of a coronary blood vessel, in a mammal, particularly a human, that includes administering a compound of the formula 1
    Type: Application
    Filed: November 12, 2002
    Publication date: September 25, 2003
    Inventors: Mitchell Glass, Jean-Claude Tardif
  • Publication number: 20030120142
    Abstract: The present invention relates to a method for visual identification of atrial tissue comprising the steps of visualizing a site of atrial tissue formation using a device adapted for visualizing and obtaining an image; and analyzing the image to determine the presence, location and/or distribution of atrial tissue in the site. The present invention also relates to a method for the treatment of atrial fibrillation in a patient, comprising the steps of identifying atrial tissue in a site of atrial tissue formation by introducing a device adapted for visualization into the site; and substantially ablating atrial tissue previously identified. The present invention further relates to a method for determining the shape of an atrial tissue formation comprising the step of identifying atrial tissue site potential indicative of the shape of the atrial tissue.
    Type: Application
    Filed: September 25, 2002
    Publication date: June 26, 2003
    Inventors: Marc Dubuc, Peter Guerra, Jean-Claude Tardif
  • Patent number: 6214887
    Abstract: Probucol exerts a positive effect on vascular remodeling. By using probucol to promote vascular remodeling by the method of the invention, favorable results can be obtained in treating such diseases and conditions as restenosis following transluminal coronary angioplasty, intimal smooth muscle cell hyperplasia, vascular occlusion, or restenosis following transluminal angioplasty or atherectomy procedures performed on the coronary, iliac, femoral, renal or carotid arteries. This effect was determined based upon an IVUS substudy from the MVP trial. Beginning 30 days before PTCA, 317 patients were randomly assigned to receive either probucol, multivitamins, the combination of drugs, or placebo. Patients were then treated for six months after PTCA. 96 patients (111 segments) underwent IVUS examination immediately after angioplasty and at follow-up. The anatomic cross-section selected for serial analysis was the one at the angioplasty site with the smallest lumen area at follow-up.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: April 10, 2001
    Assignee: Quatro Scientific, Inc.
    Inventors: Gilles Cô ;té, Jean-Claude Tardif